Abstract The anti-inflammatory/immunoparalytic phase of the systemic inflammatory response syndrome (SIRS) following major insult (surgery, thermal/traumatic injury) is of major clinical importance in the neonate, during which the risk of infection is particularly great. Here, the mechanisms by which TNF-a production is suppressed in response to infection are largely unknown. We questioned whether TNF-a itself could be a critical mediator of this suppression. Monocytes, isolated from cord blood (n=3), were treated with LPS (100 ng/ml), TNF-a (10 ng/ml, +/À anti-TNF-a antibody) for 18 and 36 h. Cells were then restimulated with LPS (Gram Àve) or Pam-3-Cys (Gram +ve) for 24 h. This was also done in the presence of selective inhibitors of MAP kinases p38, MEK and JNK. TNF-a, IL-6, IL-10 and IL-8 were quantified by ELISA CD86 and HLA-DR expression were determined flow cytometrically. Cells stimulated with LPS for 24 h produced TNF-a (282 pg/ ml), IL-10 (1,236 pg/ml), IL-6 (2,694 pg/ml) and IL-8 (2,144 pg/ml). In cells pre-exposed to TNF-a for 36 h, there was a significant suppression in TNF-a and IL-6 levels (9 and 221 pg/ml, respectively) (P<0.05) with minimal impact on IL-10 (1,206 pg/ml) and IL-8 levels (1,886 pg/ml). A similar effect was seen with Pam-3-Cys with a tenfold decrease in levels of TNF-a and IL-6 (86 fi 8.5 pg/ml and 458 fi 46 pg/ml, respectively) with no effect on IL-10 and IL-8 levels. Anti-TNF-a antibody negated this effect. Inhibition of p38 kinase reversed the TNF-a effect. Inhibition of the JNK and MEK kinases had no effect. A reduction in the expression of CD86 and HLA-DR was observed. This ex-vivo model of non-septic SIRS demonstrates that TNF-a, released during a major insult, can suppress subsequent monocyte responses to bacterial agents through p38 MAP kinase, making it a potential therapeutic target.
Introduction
The systemic inflammatory response syndrome (SIRS) occurs where there is inappropriate activation of the immune system [1] . While the initiating events leading to SIRS may be varied, e.g. sepsis, thermal injury, trauma or post major surgery, the subsequent immune pathophysiology following these events is identical [2] . The characteristics of this syndrome are initial massive release of pro-inflammatory cytokines, principally TNF-a and IL1-b followed by anergy of the immune system termed ''immunoparalysis'' and production of the antiinflammatory cytokines IL-10 and TGF-b termed the ''compensatory anti-inflammatory response'' (CARS) [2, 3] . Recent work in both adult [4, 5] and paediatric populations [6, 7] has identified monocyte and macrophage deactivation, which occurs as part of the immunoparalytic phenomenon, as a major predictor for the development of nosocomial infection with restoration of cellular function associated with improvement in the clinical condition of patients [8, 9] . Improved understanding of the factors causing monocyte/macrophage deactivation has been aided by the realisation that the ex vivo tolerant monocyte possesses the same functional phenotype as its in vivo immunoparalytic counterpart [10] [11] [12] . Innate tolerance was originally described with respect to endotoxin and is classically defined as failure of a secondary TNF-a response from a macrophage/ monocyte following initial low dose stimulation [13, 14] .
There has been no published literature regarding neonatal innate tolerance despite its importance in the development of nosocomial infections, an important predictor of mortality in the critically ill neonate [15] . The aim of this study was to assess the ability of neonatal monocytes to undergo tolerance induction. In order to mimic the clinical situation of sepsis, lipopolysaccharide [LPS] and Pam-3-Cys were used. LPS is found in the cell wall of gram-negative bacteria and signals through toll-like receptor (TLR) 4 while Pam-3-Cys is an agonist of TLR2, the surface receptor for gram-positive bacteria [16] . Recreation of the nonseptic situation was performed by exposing neonatal monocytes to TNF-a, representing the initial non-septic insult e.g. surgery and then restimulating these monocytes with LPS or Pam-3-Cys representing the bacterial challenge which the critically ill post-operative neonate commonly encounters in the intensive care environment.
Material and methods

Materials
IMDM and HBSS were purchased from BioWhitaker (Wokingham, UK). Human recombinant TNF-a and anti-human TNF-a antibody were purchased from R and D systems (Oxon, UK). LPS (Escherichia coli serotype 055:B5) was obtained from Sigma-Aldrich (Dublin, Ireland). (18)-lysine·3 HCL) was obtained from EMC microcollections (Tuebingen, Germany). Anti-human CD14(PE) CD45 (FITC) mouse anti-human CD45(clone MOPC-21)IgG1, mouse anti-human (clone 2D1M/P)IgG2a human anti-TNF(APC) and mouse anti-human (clone Mab11)IgG1 were purchased from BD Biosciences (Oxford, UK). SB203580, PD98059, SP600125, SB202474 and JNK inhibitor negative control, N-methyl-1,9-pyrazoloanthrone were purchased from Calbiochem (Nottingham, UK).
Every effort was made to ensure minimal contamination with LPS in our system. All steps in monocyte purification protocols and culturing were conducted using certified non-pyrogenic plastics (Corning/Costar, Bucks, UK) and media certified to have an endotoxin level of 0.005 endotoxin U/ml (BioWhittaker). All solutions were made up with endotoxin-free water (Nanopure, Barnstead, UK)
Monocyte isolation
Cord blood was obtained with full consent following full-term normal deliveries. This was then diluted 1/1 with HBSS. PBMCs were separated by density centrifugation through Ficoll-Hypaque (Lymphoprep, Nycomed, Oslo, Sweden), washed twice in cold HBSS and resuspended in IMDM (1 ml) and PBMC count determined by ethidium bromide and acridine orange staining. Monocytes were isolated from PBMCs by negative selection according to the manufacturer's protocol (Miltenyi Biotec, Surrey, UK). Monocyte purity, determined flow cytometrically using two-colour flow cytometric analysis (CD14/CD45), was >80%.
Analysis of cytokines
Cytokine concentrations in the cellular supernatants were determined by ELISA using TNF-a-matched Ab pairs (R&D Systems) and OptEIA human IL-10, IL6 and IL-8 sets (BD Pharmingen, Oxford, UK). Assays were performed according to the instructions provided. Colour development was assessed using a VERSA-max microplate reader (Biosciences, Dublin, Ireland). Intracellular cytokine estimation was performed as described previously [19] . Cells were stained with surface markers CD14FITC, CD45PerCp, HLA-DRPE, CD86FITC and CD80 Cy-chrome (BD, Pharmingen) at room temperature for 10 min. Cells were washed with ice-cold PBS and following this were fixed with Cytofix (Pharmingen, San Diego, USA) for 20 min at 4°C. Cells were then permeabilised with ice-cold permwash (Pharmingen, San Diego, USA), washed and resuspended in 100 ll of PBA. The intracellular antibody TNF-aAPC was then added for 30 min at room temperature. The cells were then washed in ice-cold permwash, resuspended in 200 ll of PBA and assessed by flow cytometry.
Statistical analysis
The Mann-Whitney non-parametric test was performed using the software SPSS for Windows.
Results
We first examined the primary cytokine output from the proposed tolerising agents. Figure 1a demonstrates the cytokine output from neonatal monocytes stimulated with LPS. There is significantly less (P<0.005) TNF-a and IL-10 production from neonatal monocytes in comparison to their adult counterparts. Interestingly, there are comparable levels of IL-1b, IL-6 and IL-8 production. Pam-3-Cys is not as potent a stimulus as LPS and this is reflected in Fig. 1b where there is a global reduction in measured cytokine levels. Neonatal monocytes produce significantly less (P<0.01) TNF-a and IL-10 in relation to their adult counterparts in common with Fig. 1a . Similarly IL1-b, IL-6 and IL-8 levels are comparable with adult monocytes. TNF-a stimulation of neonatal and adult monocytes is shown in Fig. 1c . There is a significant reduction (P<0.05) in the amount of IL-10 produced from neonatal monocytes with no significant attenuation noted in relation to IL-6 and IL-8. There were no measurable levels of IL-1b produced from either neonatal or adult monocytes. TNF-a could not be measured by ELISA due to the presence of exogenous TNF-a in the cellular supernatant. Neonatal monocytes are capable of undergoing tolerance to LPS and Pam-3-Cys with the same time kinetic as adult monocytes (Fig. 2a) . Innate tolerance is defined as a lack of TNF-a production on secondary stimulation. Neonatal monocytes treated with either LPS or Pam-3-Cys and then restimulated 18 hr later with higher doses of the same stimulus for a further 24 h failed to produce TNF-a in comparison to those cells which did not receive the initial low dose stimulation. We next looked at TNF-a as an inducer of tolerance. The current dogma is that TNF-a is not capable of tolerance induction [20, 21] . This is shown in Fig. 3a where at 18 h there is still a substantial secondary TNFa response following secondary LPS or Pam-3-Cys stimulation. Interestingly, when the TNF-a pre-treatment time kinetic is extended to 36 h, TNF-a causes tolerance as judged by lack of TNF-a production on secondary stimulation with LPS and Pam-3-Cys. Substantial amounts of IL-10 and IL-8 are produced from these TNF-a tolerant cells with a significant reduction in IL-6 secretion (P<0.05), in keeping with the idea that tolerant cells exhibit a reorientation of their functional phenotype as opposed to a global reduction in the cytokine producing capacity of the monocyte.
Further evidence that TNF-a is acting as a tolerising agent is provided by analysis of the surface antigens CD86 and HLA-DR. Downregulation of both HLA-DR and CD86 is present in the TNF-a tolerant cell in common with published results on LPS tolerance induction [22] (Fig. 4a, b) .
Neutralisation of TNF-a was performed using anti-TNF-a antibody to ensure that the results obtained were due exclusively to TNF-a. In the presence of anti-TNFa, tolerance does not occur as evidenced by a substantial TNF-a response following secondary LPS stimulation (Fig. 5a) . To elucidate the mechanisms of TNF-a tolerance induction, specific inhibitors of the MAP kinase pathway were employed. The MAP kinase pathway is one of the chief pathways activated by TNF-a [23, 24] . The MAP kinase proteins ERK, JNK and p38 are phosphorylated leading to activation of downstream mediators resulting in gene transcription and ultimately cytokine production [25] .
The inhibitors SP600125, PD98059 and SB 203580 prevent phosphorylation of JNK, ERK and p38, respectively [26] [27] [28] . While inhibition of ERK and JNK does not prevent TNF-a from inducing tolerance, inactivation of p38 by SB 203580 does, as evidenced by a substantial TNF-a response upon secondary LPS stimulation (Fig. 5b) .
Discussion
There has been much discussion in the literature over the last decade regarding the role of the monocyte in the neonatal immune response. The rapidity of clinical deterioration in septic neonates suggests an inefficiency Fig. 1 A quantity of 0.5·10 6 /ml of neonatal and adult monocytes were cultured in IMDM/10% autologous serum and stimulated with a LPS (1 lg/ml), b Pam-3 Cys (1 lg/ ml) or c human recombinant TNF-a (1 lg/ml) for a period of 24 h. Following this time point the cellular supernatant was collected and stored at À70°C until analysed by ELISA (n=6). Data representative of mean ± SD Fig. 2 A quantity of 0.5·10 6 /ml neonatal and adult monocytes were cultured for 18 h with LPS (100 ng/ml) or Pam-3-Cys (100 ng/ml) for 18 h. The cells were then washed twice and restimulated with LPS (1 lg/ml) or Pam-3-Cys (1 lg/ml) for a further 24 h. The cellular supernatant was collected and stored at À70°C until analysed. TNF-a was measured by ELISA (n=5). Data representative of mean ± SD of the innate immune system to mount an effective response allowing rapid progression to multiple organ dysfunction [29] .The data presented here agrees with the published literature demonstrating that neonatal monocytes produce equivalent levels of IL-6, IL-8 and IL1-b, with TNF-a the only element of the pro-inflammatory response to exhibit reduced levels following LPS and Pam-3-Cys stimulation [30] [31] [32] [33] . The results also show that IL-10 production is significantly reduced in relation to adult monocytes following stimulation with LPS, Pam-3-Cys and TNF-a. Signal transduction of LPS and Pam-3-Cys occurs via the surface receptors TLR4 and TLR 2, respectively [17, 34] . Activation of these surface receptors ultimately leads to gene transcription of both pro-and anti-inflammatory cytokines [35] . The finding that neonatal monocytes produce comparable levels of the pro-inflammatory cytokines IL-6, IL-8 and IL-1b suggests, in agreement with published studies [30] , that similar amounts of TLR receptors are present on the cell surface of neonatal monocytes and that the discrepancies seen in relation to TNF-a and IL-10 production as illustrated here are due to distinct inherent deficiencies present in the neonatal monocyte in relation to the pathways involved specifically in TNF-a and IL-10 production. This data coupled with published work on the other main anti-inflammatory cytokine TGF-b illustrate clearly that both components of the neonatal anti-inflammatory response are deficient [36] . One could argue that a factor leading to rapid deterioration of the septic neonate is inefficient counterbalancing of the anti-inflammatory component of the inflammatory response resulting in a predominance of the pro-inflammatory element of the neonatal innate immune response occurring as a result of inherent deficiencies within the neonatal cell as opposed to the virulence of the infecting organism as is the case in adults.
Inappropriate monocyte activation is central to the initiation and progression of SIRS. Activation of monocytes following any major insult results in massive and inappropriate release of the pro-inflammatory cytokines TNF-a, IL1-b, IL-6 and IL-8 [37] . In large quantities these cytokines cause a reduction in vascular tone and myocardial contractility resulting in hypotension [38] . They also stimulate release of tissue factor, a potent activator of coagulation, from endothelial cells and cause a reduction in expression of thrombomodulin, an inhibitor of coagulation, resulting in intravascular thrombosis [39] . Fig. 3 A quantity of 0.5·10 6 /ml neonatal monocytes were stimulated with TNF-a (10 ng/ ml) for 18 and 36 h. These cells were then washed extensively and restimulated with LPS (1 lg/ml) or Pam-3-Cys (1 lg/ ml) for a further 24 h. Following this time period cellular supernatant was collected and stored at À70°C until further analysis. TNF-a, I L-10,IL-6 and IL-8 were measured by ELISA (n=3). Data representative of mean ± SD Fig. 4 A quantity of 0.5·10 6 /ml neonatal monocytes were stimulated with TNF-a (10 ng/ml) for 36 h. Cells were then washed twice and restimulated with LPS (1 lg/ml) for a further 24 h. Cells were harvested and stained for 30 min with a CD86 and b HLA-DR.
Following this time period, cells were assessed for surface expression of both molecules by flow cytometry (n=3). Data representative of mean ± SD The net effect of these events is hypoxia of tissues and organs, causing ischemic injury, further activating the immune response and a viscous cycle ensues [40, 41] . From an immunological standpoint, the mechanisms governing the inflammatory response are disrupted due to the inappropriate pro-inflammatory response and a prolonged period of immunoparalysis and predominance of anti-inflammatory cytokine production ensues. This period in SIRS has also been referred to as ''CARS'' [2, 36] .
Monocytes from patients in CARS are identified as failing to mount a secondary TNF-a response following stimulation and also exhibit a downregulation of the surface receptors CD86 and HLA-DR [42] [43] [44] . These receptors are important in presentation of the foreign antigen to the T cells of the adaptative immune system and so activation of the adaptative immune system is hindered while this downregulation is present [45] . Not surprisingly, patients are more susceptible to invading organisms during this period causing further monocyte activation and a viscous cycle is created leading to multiple organ dysfunction syndrome (MODS) with its associated high mortality rates.
The monocyte phenotype from patients in CARS is identical to the ex-vivo tolerant monocyte [10] [11] [12] allowing ex vivo investigation into the many mediators involved in the creation of the immunoparalysis witnessed in the CARS phase of SIRS.
The results from our study illustrate that neonatal monocytes are capable of tolerance induction by LPS and Pam-3-Cys in a manner identical to their adult counterparts. This implies that similar kinetics of immunoparalysis exist in the septic Gram-positive and Gram-negative neonate making therapeutic interventions, e.g. the use of interferon gamma to reverse immunoparalysis, already successfully tried in the adult population, a distinct possibility in the neonatal population [8, 9] .
The immune pathophysiology which occurs in the non-septic SIRS situation is identical to that in the septic SIRS situation. While it is agreed that endotoxin is the main cause of immunoparalysis in septic SIRS, the causal agents in the non-septic situation have been harder to define. Reductionist ex vivo investigation into the mechanisms of tolerance has identified possible roles for IL1-b, prostaglandins, corticosteroids and IL-10 [21, [46] [47] [48] .
Interestingly, despite early in vivo adult work demonstrating evidence of TNF-a tolerance induction using end points of survival and weight loss [49] [50] [51] , more recent ex vivo studies have failed to demonstrate any role for this cytokine in tolerance induction [20, 52, 53] .
The data presented here shows that in the neonatal monocyte population TNF-a is capable of inducing tolerance by extension of the tolerising time kinetic. The 36 h kinetic was chosen in an attempt to mirror the Monocytes were stimulated for 36 h with TNF-a (10 ng/ml) in the presence or absence of the MAP kinase inhibitors SB203580 (10 lM/ml), PD 98059 (10 lM/ml) and SP600125 (10 lM/ml). Following this time period, the cells were washed extensively and restimulated with LPS (1 lg/ml) for a further 24 h. The cellular supernatant was harvested and stored at À70°C until cytokine estimation was performed using ELISA (n=3). Data representative of mean ± SD longer time point present in the in-vivo work. This finding is strengthened by our results which also show a downregulation of CD86 and HLA-DR in keeping with the tolerant phenotype described in the literature. Tolerance is achieved by TNF-a through activation of the p38 pathway. Interestingly, other investigators have also shown this result in relation to LPS tolerance induction in adult cells [54] . This novel finding provides evidence for the first time that TNF-a, the archetypal proinflammatory cytokine, displays anti-inflammatory properties by virtue of its involvement in the creation of immunoparalysis in the non-septic SIRS situation. The identification of p38 as the critical molecule involved helps to provide a framework for the development of a potential therapeutic target in the management of nonseptic SIRS patients in the future.
